Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Amarin Corp.’s stock rises in the extended session Friday after being halted for half the trading day as the pharmaceutical company hikes its sales outlook following a Food and Drug Administration marketing approval that gives its drug Vascepa a wider use.